louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00169351: National Gilles De La Tourette Study Group
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Tourette Syndrome
Lead sponsor: Groupe Hospitalier Pitie-Salpetriere
Sponsor class: OTHER
Collaborators: name: Institut National de la Santé Et de la Recherche Médicale, France
First posted: 2005-09-15
Sex: ALL
Minimum age (years): 15
Maximum age (years): 80
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: DEFINED_POPULATION
Time perspective: PROSPECTIVE

Brief summary: Tourette syndrome is rare. In France, about 3000 patients have a severe form of the disease. The aim of this study is to collect clinical characteristics in 200 patients with Tourette syndrome.


Eligibility criteria: Inclusion Criteria:

* Tourette syndrome

Exclusion Criteria:

* severe cognitive disorders

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Paris
country: France
facility: Centre d'Investigation Clinique-HÔPITAL PITIÉ-SALPETRIERE
Study officials:
affiliation: Groupe Hospitalier Pitié-Salpêtrière
name: Yves Agid, MD, PhD
role: STUDY_DIRECTOR
References:
citation: Worbe Y, Mallet L, Golmard JL, Behar C, Durif F, Jalenques I, Damier P, Derkinderen P, Pollak P, Anheim M, Broussolle E, Xie J, Mesnage V, Mondon K, Viallet F, Jedynak P, Ben Djebara M, Schupbach M, Pelissolo A, Vidailhet M, Agid Y, Houeto JL, Hartmann A. Repetitive behaviours in patients with Gilles de la Tourette syndrome: tics, compulsions, or both? PLoS One. 2010 Sep 24;5(9):e12959. doi: 10.1371/journal.pone.0012959.
Clinical trial NCT05433051: A Comparison of Two Protocol for Maxillary Molar Intrusion Buccal Miniscrew and TPA Versus Vertical Holding Appliance
Official title: A Comparison of Two Protocol for Maxillary Molar Intrusion Buccal Miniscrew and TPA Versus Vertical Holding Appliance Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: NA
Conditions: Dental Intrusion
Mandibular Rotation
ANB , SNA, SNB
Openbite Teeth &#X7C; Teeth and Gum &#X7C; Dental
Keywords: TPA
Miniscrew
intrusion
vertical holding appliance
cephalometry
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-06-27
Enrollment: 24
Sex: ALL
Minimum age (years): 14
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: this study is to compare the dental and skeletal changes caused by the intrusion of maxillary first molars buccal miniscrew and TPA versus vertical holding appliance using lateral cephalometry.


Eligibility criteria: Inclusion Criteria:

* Patients suffering class I or II with AOB.
* AOB ranged between 3-7 mm assessed from cephalometry.
* Patients with excess in posterior dentoalveolar height according to Burrstone .
* Patients with good oral hygiene and general health.
* Patients with no previous orthodontic treatment.
* Good quality of lateral cephalometry.

Exclusion Criteria:

* Skeletal open bite
* previous orthodontic treatment

Primary outcomes:
measure: amount of dental
timeFrame: Post-intervention at 6 months
measure: amount of skeletal changes
timeFrame: Post-intervention at 6 months
measure: amount of skeletal changes
timeFrame: Post-intervention at 6 months
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Mohamed Shendy
state: Nasr City
Study officials:
References:
Clinical trial NCT00758251: Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment
Official title: Observation of Change in Clinical Global Impression Scores in Schizophrenia Patients Receiving Seroquel XR Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Schizophrenia
Keywords: Schizophrenia
Seroquel XR
CGI
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2008-09-25
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: primary care clinics

Brief summary: The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Eligibility criteria: Inclusion Criteria:

* Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
* Signed and dated Patient Informed Consent (ICF)

Exclusion Criteria:

* Hypersensitivity to the active substance or to any of the excipients of Seroquel XR

Primary outcomes:
measure: Improvement in CGI scores and BPRS comparing visits 1 and 3.
timeFrame: twice with 4 week interval
Secondary outcomes:
measure: To evaluate compliance to therapy
timeFrame: twice with 4 week interval
Other outcomes:
Locations:
city: Bauska
country: Latvia
facility: Research Site
city: Cesis
country: Latvia
facility: Research SIte
city: Daugavpils
country: Latvia
facility: Research Site
city: Dobele
country: Latvia
facility: Research Site
city: Jekabpils
country: Latvia
facility: Research Site
city: Jelgava
country: Latvia
facility: Research Site
city: Jurmala
country: Latvia
facility: Research Site
city: Kuldiga
country: Latvia
facility: Research Site
city: Liepaja
country: Latvia
facility: Research Site
city: Riga
country: Latvia
facility: Research Site
city: Saldus
country: Latvia
facility: Research Site
city: Strenci
country: Latvia
facility: Research Site
city: Talsi
country: Latvia
facility: Research Site
city: Tukums
country: Latvia
facility: Research Site
city: Valmiera
country: Latvia
facility: Research Site
Study officials:
affiliation: AstraZeneca Latvia
name: Agrita Hartmane
role: STUDY_DIRECTOR
References:
Clinical trial NCT02358551: Comparison of Axillary Vein Puncture With Subclavian Vein Puncture in Pacemaker Implantation
Official title: Comparison of Axillary Vein Puncture With Subclavian Vein Puncture in Pacemaker Implantation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mechanical Complication of Cardiac Pacemaker
Keywords: Pacemaker
Axillary Vein
Subclavian vein
Clinical Study
Cardiovascular implantable electronic devices
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2015-02-09
Enrollment: 220
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The intrathoracic subclavian venous technique for pacemaker implantation may be associated with serious complications. Axillary vein puncture tends to reduce lead implantation complications such as pneumothorax and lead crush, but clinical adoption is not widely acknowledged, especially in China, although this approach has been proposed for 20 years. The major concern is the learning curve for axillary vein puncture and its success rate. The investigators try to prove that the success rate of axillary vein puncture is non-inferior to subclavian vein puncture, hence to promote the clinical application of axillary vein puncture to reduce pacemaker implantation complications.


Eligibility criteria: Inclusion Criteria:

* Patients with indication of pacemaker or ICD implantation
* Personally signed and dated informed consent document

Exclusion Criteria:

* Accompanied with malignant disease or other disease, which cause life expectancy \< 1 year.
* Anatomical variation of axillary vein or subclavian vein, unable to puncture.
* Poor compliance for follow-up.
* Patients with any condition which, in the investigator's judgment, not suitable for enrollment.

Primary outcomes:
measure: Success rate of vein puncture
timeFrame: 1 Day
Secondary outcomes:
measure: Mechanical complication of electrode lead (combined endpoints of hemothorax, pneumothorax, air embolism, inadvertent arterial puncture, hematoma, fracture of electrode lead, nerve injury and subclavian crush syndrome)
timeFrame: 6 months
measure: Duration of pacemaker implantation
timeFrame: 1 Day
Other outcomes:
Locations:
city: Beijing
country: China
facility: China-Japan Friendship Hospital
Study officials:
affiliation: China-Japan Friendship Hospital
name: Xianlun Li, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Liu P, Zhou YF, Yang P, Gao YS, Zhao GR, Ren SY, Li XL. Optimized Axillary Vein Technique versus Subclavian Vein Technique in Cardiovascular Implantable Electronic Device Implantation: A Randomized Controlled Study. Chin Med J (Engl). 2016 Nov 20;129(22):2647-2651. doi: 10.4103/0366-6999.193462.
Clinical trial NCT01132651: Cooling Pillow for Atopic Dermatitis
Official title: Novel Use of a Cooling Pillow for Treatment of Severe Hand and Neck Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atopic Dermatitis
Eczema
Keywords: eczema
itch
pruritus
head
neck
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2010-05-28
Enrollment: 9
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to see if using a cooling pillow at night will help sleep quality in people with atopic dermatitis (AD).


Eligibility criteria: Inclusion Criteria:

* Diagnosis of AD by dermatologist
* AD located on the head and neck
* Investigator Global Assessment (IGA)score \>3 at time of enrollment
* Able to read, write, and understand study materials
* Age 18 or older

Exclusion Criteria:

* Concurrent non-AD skin disease on the head and neck
* Active skin infection on the head and neck, or conditions that may interfere with evaluation of the skin

Primary outcomes:
measure: Change in Sleep Quality as Measured by a Change in Pittsburgh Sleep Quality Index (PSQI) Survey Score
timeFrame: Baseline and at 2 weeks
Secondary outcomes:
measure: Change in Severity of Atopic Dermatitis (AD) as Measured by a Change in Investigator Global Assessment (IGA) Score
timeFrame: Baseline and at 2 weeks
Other outcomes:
Locations:
city: Chicago
country: United States
facility: Northwestern University Feinberg School of Medicine, Department of Dermatology
state: Illinois
Study officials:
affiliation: Northwestern University
name: Dennis West, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01910051: Explorative Assessment of Biomarkers in Overweight and Obese Subjects
Official title: Explorative Assessment of Biomarkers Indicative of Insulin Resistance and Prediabetes in Overweight and Obese Subjects
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Prediabetes
Lead sponsor: Profil Institut für Stoffwechselforschung GmbH
Sponsor class: INDUSTRY
First posted: 2013-07-29
Enrollment: 106
Sex: ALL
Minimum age (years): 18
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Generally healthy or Type 2 Diabetes mellitus

Brief summary: The rationale for this trial is to apply a simple and minimally strenuous pre-screening approach prior to performing more extensive trial-specific screening and baseline-characterization activities in the resulting pre-selected population of subjects.

Detailed description: The pre-screening assessments are designed to characterize the metabolic risk profile / prediabetic status in an unselected population of overweight and obese volunteers, aiming to pre-select high risk and prediabetic subjects as a target population who may specifically profit from primary diabetes intervention (prevention) strategies.

Eligibility criteria: Inclusion Criteria:

* Obese and overweight subjects
* Considered generally healthy

Exclusion Criteria:

* Clinically significant acute illness within 2 weeks before study procedures

Primary outcomes:
measure: anthropometric measures and metabolic biomarkers indicative of prediabetes
timeFrame: Day one
Secondary outcomes:
measure: intra-subject and inter-subject variability of analyzed biomarkers
timeFrame: within one month
Other outcomes:
measure: the correlation between anthropometric data, medical history, and biomarkers with regard to metabolic risk
timeFrame: up to 3 years
Locations:
city: Neuss
country: Germany
facility: Profil Institut für Stoffwechselforschung GmbH
Study officials:
affiliation: Profil Institut für Stoffwechselforschung GmbH
name: Leona Plum-Mörschel, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00753051: Treat Clozapine ( CLZ )-Resistant Schizophrenia Comparing CLZ + Haloperidol vs. CLZ + Electroconvulsive Therapy (ECT)
Official title: Treatment of Clozapine-resistant Schizophrenia : Comparison Between Augmentation With Haloperidol and Electroconvulsive Therapy
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Schizophrenia
Keywords: clozapine-resistant schizophrenics
haloperidol augmenting clozapine
electroconvulsive therapy augmenting clozapine
Lead sponsor: Khon Kaen University
Sponsor class: OTHER
First posted: 2008-09-16
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Clozapine treatment resistant schizophrenia is still prevalent.The effectiveness of augmenting clozapine : one augmenting with haloperidol and the other with electroconvulsive therapy should be determined.This study is a randomized control trial.


Eligibility criteria: Inclusion Criteria:

1. schizophrenic patients diagnosed with schedules for clinical assessment in neuropsychiatry ( SCAN )in accordance with DSM-IV-TR or ICD-10
2. Resistant to at least 6 weeks of clozapine treatment in therapeutic dosage
3. Voluntary to participate the research protocol expressed by signing informed consent form

Exclusion Criteria:

1. Patient does not volunteer himself or herself
2. Patient is having epilepsy, DM, cardiac disease, autistic disorder and illiterate
3. Patient is deaf, blind , dumb to obstruct good communication

Primary outcomes:
measure: PANSS , HAM-D , CGI , AIMS Scores
timeFrame: every 4 weeks for 24 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Muang
country: Thailand
facility: Department of Psychiatry.Faculty of Medicine.KhonKaen University.
state: KhonKaen
Study officials:
affiliation: Department of Psychiatry.Faculty of Medicine.Khon Kaen University
name: Suchat Paholpak, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05371951: Effect of Erchonia Laser on Erectile Dysfunction
Official title: A Pilot Evaluation of the Effect of the Erchonia® HLS™ on Individuals With Erectile Dysfunction
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Erectile Dysfunction
Lead sponsor: Erchonia Corporation
Sponsor class: INDUSTRY
First posted: 2022-05-12
Enrollment: 0
Sex: MALE
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to see if applying low-level laser light can provide improvement in erectile dysfunction

Detailed description: The purpose of this pilot study is to determine the effectiveness of the Erchonia® HLS™, manufactured by Erchonia Corporation (the Company), in providing improvement in erectile dysfunction.

Eligibility criteria: Inclusion Criteria:

* Male between 40 and 80 years old
* Known or suspected vasculogenic ED based on clinical history
* In an active sexual relationship with a minimum of 2 sexual attempts per month for at least one month prior to enrollment
* Suffering from ED for at least 6 months
* Testosterone level between 300 - 1000ng/dL within one month prior to enrollment
* Hgb A1C less than or equal to 8% within one month prior to enrollment
* Total IIEF-EF scores between 8-25
* EHS score greater than or equal to

Exclusion Criteria:

* ED due to radical prostatectomy, prior pelvic surgery, or radiation therapy to the pelvis within 12 months prior to enrollment
* Men with known neurogenic or psychogenic ED
* Anatomic malformations of the penis including Peyronie's disease
* Testosterone greater than 300ng/dL or 1000ng/dL
* Hgb A1C greater than 8%
* International Normalized Ratio greater than 2.5, and men on any blood thinners other than 81mg aspirin
* Active testicular or prostate cancer

Primary outcomes:
measure: Total Score on the International Index of Erectile Function - Erectile Function
timeFrame: 6 week
Secondary outcomes:
measure: Total Erection Hardness Score
timeFrame: 6 week
Other outcomes:
Locations:
city: Richmond
country: United States
facility: Ranjodh S. Gill, MD, FACP
state: Virginia
Study officials:
References:
Clinical trial NCT01223651: Performance of Continuous Glucose Monitoring Systems at Altitude
Official title: Performance of Continuous Glucose Monitoring Systems at Altitude.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Diabetes Mellitus, Type 1
Keywords: Diabetes Mellitus, Type 1
Continuous Glucose Monitoring System
Accuracy
Altitude
Lead sponsor: The Royal Bournemouth Hospital
Sponsor class: OTHER
First posted: 2010-10-19
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: 10 healthy volunteers will undergo the controlled lowering of their blood glucose level at sea level and a simulated altitude of 8,000 feet, to test the hypothesis that continuous glucose monitoring system measurement of blood glucose is as accurate at altitude as at sea level.


Eligibility criteria: Inclusion Criteria:

* Age 18 - 60 years.
* No known medical conditions or concomitant medication.

Exclusion Criteria:

* Pregnancy.
* Marine diving in preceding 24 hours.
* Unable to provide written informed consent.

Primary outcomes:
measure: Accuracy of continuous glucose monitoring system (CGMS).
timeFrame: One year.
Secondary outcomes:
measure: The effect of altitude on the recognition of hypoglycaemic symptoms.
timeFrame: One year.
Other outcomes:
Locations:
city: Henlow
country: United Kingdom
facility: Royal Airforce Base Henlow
state: Bedfordshire
city: Bournemouth
country: United Kingdom
facility: Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
state: Dorset
Study officials:
affiliation: Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
name: Joseph Begley, Doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03692351: Osteolysis Development Around Uncemented Cups With or Without Screw Holes
Official title: Osteolysis Development Over Time Around Uncemented Titanium Fiber Mesh Cups With or Without Screw Holes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Arthroplasty Complications
Keywords: uncemented hip arthroplasty
osteolysis
polyethylene wear
implant design
Lead sponsor: Sahlgrenska University Hospital
Sponsor class: OTHER
Collaborators: name: Zimmer Biomet
First posted: 2018-10-02
Enrollment: 95
Sex: ALL
Minimum age (years): 30
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In order to investigate the role of acetabular cup screw holes for the transport of osteolysis-inducing particles in a total hip arthroplasty articulation, the investigators compare the amount of bone loss around acetabular cups with and without holes. Bone loss is measured with computed tomography at 7 years and 15 - 18 years of follow-up.

Detailed description: Particles generated by wear and corrosion within an artificial hip articulation can cause biologically mediated bone loss in the surrounding pelvis. Particles can be found within immunologically active cells inside bone lesions. Holes intended for screw fixation in uncemented acetabular cups are believed to be a main route for these particles from the articulation into the pelvic bone. Using pressfit, screws are not always necessary for a successful fixation of an uncemented cup. The investigator's hypothesis is that a pressfit fixated cup without screw holes will display a decreased amount of periacetabular osteolysis compared to a cup with screw holes. Therefore, 95 hips (90 patients) were randomized to receive either pressfit cups without screw holes or the same type of cup with screw holes. The occurence and size of periacetabular osteolysis will be compared between the two groups. In addition, since the patients will have a computed tomography examination at 7 years and between 15 and 18 years the investigator will also analyze development of periacetabular osteolysis over time. The different cups were paired with three different types of femoral stems. Also, articulation wear and cup and stem fixation will be analyzed using radiostereometry.

Eligibility criteria: Inclusion Criteria:

* primary or secondary osteoarthritis

Exclusion Criteria:

* Inflammatory osteoarthritis, hip joint infection

Primary outcomes:
measure: Periacetabular osteolysis frequency change between 7 and 18 years
timeFrame: Change between 7 to 18 years after surgery
measure: Periacetabular osteolysis size change between 7 and 18 years
timeFrame: Change between 7 to 18 years after surgery
Secondary outcomes:
measure: Cup fixation (translation)
timeFrame: 18 years postoperatively
measure: Cup fixation (rotation)
timeFrame: 18 years postoperatively
measure: Polyethylene wear
timeFrame: 18 years postoperatively
Other outcomes:
Locations:
Study officials:
References: